Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment

Annals of Oncology

Volumn 19, Issue 8, 2008, Pages 1485-1487

  Cartron, Guillaume ^a,b   Ohresser, M ^a   Salles, G ^c   Solal Celigny P ^d   Colombat, P ^e   Watier, H ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CENTRE JEAN BERNARD   (France)

^e CHU BRETONNEAU   (France)

Author keywords

Fc RIIIb; Follicular lymphoma; Neutrophils; Rituximab

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIIB; GRANULOCYTE ANTIBODY; GRANULOCYTE ANTIBODY 1; GRANULOCYTE ANTIBODY 2; PROTEIN BCL 2; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; BONE MARROW; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GENE REARRANGEMENT; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IN VIVO STUDY; MALE; NEUTROPHIL; OVERALL SURVIVAL; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; NEUTROPHILS; POLYMORPHISM, GENETIC; RECEPTORS, IGG;

EID: 48749097545     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn163     Document Type: Article

References (20)

1. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: Ways to improve rituximab efficacy. Blood 2004; 104: 2635-2642.
2. Cartron G, Dacheux L, Salles G at al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 2002; 98: 754-758.
3. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphism independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947.
4. Manches O, Lui G, Chaperot L et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949-954.
5. Hernandez-Ilizalturri FJ, Jupudy V, Ostberg J et al, Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgidn's lymphoma severe combined innumodeficiency mouse model. Clin Cancer Res 2003; 9: 5866-5873.
6. Nimmerjahn F, Bruhns P, Horiuchl K, Ravetch JV. FcgammaRIV: A novel FcR with distinct IgG subclass specificity. Immunity 2005; 23: 41-51.
7. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998; 76: 231-248.
8. Ravetch A Perussia B. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 1989; 170: 481-497.
9. Bredius RG, Fijen CA, De Haas M et al. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1-and IgG3-opsonized bacteria and erythrocytes. Immunology 1994; 83: 624-630.
10. Salmon JE, Edberg JC, Kmberly RP, Fc: Gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest 1990; 85: 1287-1295.
11. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol 1998; 76: 231-248.
12. Colombat P, Salles G, Brousse N et al. Rituximab (art-GD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 2001; 97: 101-106.
13. Bux J, Stein EL, Santoso S, Mueller-Eckhardt C. NA gene frequencies in the German population, determined by polymerase chain reaction with sequence-specific primers. Transfusion 1995; 35: 54-57.
14. Raymond M, Rousset F. Genopop (version 1.2) a population genetics software for exact test and ecumenicism. J Heredity 1995; 86: 248-249.
15. van der Pol WL, Jansen MD, Sluiter WJ et al. Evidence for non-random distribution of Fcgamma receptor genotype combinations. Immunogenetics 2003; 55: 240-246.
16. Colombat P, Brousse N, Morschhauser F et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up of 7 years. Blood 2006; 108: 486a.
17. Ternant D, Ohresser M, Thomas C et al. Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies. Blood 2005; 106: 1503-1504; author reply 1504-1505.
18. Hernandez-Ilizalturri FJ, Jupudy V, Reising S et al. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a sever combined immunodeficiency mouse lymphoma model. Leuk Lymphoma 2005; 46: 1775-1784.
19. van der Kolk LE, Grillo-Lopez A, Baars JW, van Oers MHJ. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: Final report on safety and efficacy. Leukemia 2003; 17: 1658-1664.
20. Loisel S, Ohresser M, Pallardy M et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007; 62: 34-42.